EE104 Appraisal of the Multi-Criteria Decision Analysis Method to Improve Value Assessment of New Therapies

Abstract

Listen

Translate article

Conventional approaches to assessing the “value” of new therapies have limited scope. There is a need to broaden the view of healthcare “value”, to promote innovation. An ISPOR task force has previously outlined a “Value Flower” of commonly and rarely examined aspects of healthcare value, and concluding that further research is needed. We propose that multi-criteria decision analysis (MCDA), a structured decision-making process which offers flexibility to incorporate multiple criteria into one appraisal, may help enhance HTA decision-making and help broaden the view of what constitutes “value”.